(NASDAQ: ETON) Eton Pharmaceuticals's forecast annual revenue growth rate of 34.76% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 7.75%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.32%.
Eton Pharmaceuticals's revenue in 2026 is $141,061,000.On average, 6 Wall Street analysts forecast ETON's revenue for 2026 to be $4,835,685,767, with the lowest ETON revenue forecast at $4,170,872,711, and the highest ETON revenue forecast at $5,437,045,950. On average, 6 Wall Street analysts forecast ETON's revenue for 2027 to be $7,837,871,926, with the lowest ETON revenue forecast at $5,740,177,629, and the highest ETON revenue forecast at $9,240,180,420.
In 2028, ETON is forecast to generate $9,956,909,462 in revenue, with the lowest revenue forecast at $7,880,558,404 and the highest revenue forecast at $12,470,508,500.